Shire Human Genetic Therapies and a string of smaller drug developers have decided to pull up stakes from Cambridge and head for the suburbs. The report says the exodus is being triggered by a desire to find less expensive digs. The city has contributed to creating one of the biggest biotech clusters in the world, but developers have been balking at the high rents they face in town. For growing companies, the desire to get everyone under one roof can be a particular challenge.
- read the article in the Boston Globe